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combination chemotherapy or carboplatin (JM8)
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Summary Between 1978 and 1983, 44 patients with advanced seminoma were treated with cis-platinum-based
combination chemotherapy (39 patients) or with carboplatin (JM8), as a single agent (5 patients). Of the total
group, 40 (90%) are alive and disease free. Two of the 4 patients who died relapsed as non-seminomatous
germ-cell tumours. Results in previously untreated patients indicate that tumour volume is less important as a
prognostic factor than in non-seminomas. Residual masses were present in almost 80% of patients 1 month
after chemotherapy; such masses regress slowly and surgery is not indicated. Elective radiotherapy after
chemotherapy appears to be inessential since relapse rates are comparable in irradiated (1/15) and
unirradiated patients (1/16). Pretreatment serum HCG concentrations did not influence the outcome of
chemotherapy. Preliminary results with JM8 suggest that it is an active single agent in the treatment of
seminoma.
Approximately 70% of patients with testicular
seminoma present without clinical evidence of
metastases (Stage I) and in the majority of the
remainder metastases appear confined to infra-
diaphragnatic nodes (Stage II) (Peckham, 1981).
The early stage presentation together with the
radiosensitivity of seminoma has resulted in
excellent survival figures (Maier et al., 1968;
Smithers et al., 1971; Castro & Gonzales, 1971;
Doornbos et al., 1975; Kademian et al., 1976; Van
der werf Messing, 1976; Calman et al., 1979;
Thomas et al., 1982). However, despite these good
overall results, subgroups can be identified where
the results of radiotherapy are less satisfactory.
These include patients with bulky Stage II disease
and Stage III and IV presentations (Ball et al.,
1982).
Experience in recent years has shown that
seminomas are responsive to the chemotherapy
used to treat non-seminomatous germ-cell tumours,
suggesting that chemotherapy could be considered
as an alternative to or in conjunction with radio-
therapy in selected patients (Einhorn & Williams,
1980; Ball et al., 1982; Morse et al., 1983; Simon et
al., 1983; Van Oosterom et al., 1984).
Patients and methods
Patients
Between October 1978 and November 1983, 44
patients aged from 23 to 56 years were treated with
chemotherapy containing cis-platinum (39 patients)
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or the platinum analogue cis-diammine-1, 1-
cyclobutane dicarboxylate platinum II (CBDCA or
JM8) as a single agent (5 patients). No patient had
received prior chemotherapy, but 13 had been
irradiated and subsequently relapsed. Of the total
group, 36 patients had primary intra-scrotal
testicular seminomas and 1 patient had a massive
seminoma in an undescended abdominal testis.
Four patients (all male) had primary mediastinal
seminomas, in two with lung infiltration and in one
with involvement of a vertebra and extradural cord
compression. Three patients had no detectable
primary tumour but on the basis of the pattern of
spread were presumed to have occult seminomas in
the testis.
The observation time from start of chemotherapy
for the series is 12 to 73 months, median 36 months.
Staging
This included chest X-ray, lymphography, CT scans
of chest and abdomen, i.v. urography and in
selected patients Gallium 67 scanning. Serum
concentrations of alphafoetoprotein (AFP) and
human chorionic gonadotrophin (HCG) were
measured initially in all patients and employed as a
monitor of disease progress thereafter.
The Royal Marsden staging classification
(Peckham et al., 1979) was employed:
Stage I:
No clinical evidence of metastases.
Stage II:
Infradiaphragmatic lymph node involvement
A - maximum diameter <2 cm
B - maximum diameter 2-5 cm
C - maximum diameter >5 cm.
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Stage III:
Supra and infradiaphragmatic node
involvement.
A, B and C as for II.
Stage IV:
Extranodal metastases A, B and C
as for II.
Lung sub-staging-
L1 1 3 metastases
L2>3 metastases all
<2cm diameter
L3 >3 metastases one or
more >2cm diameter.
H+ liver involvement other sites,
e.g. bone denoted.
Criteriafor entry to study
All patients had histologically proven pure
seminoma. Tissue stains for AFP were negative and
serum AFP concentrations within normal limits.
During the period of study there were 8 patients
with histologically pure seminoma who had either a
raised serum alphafoetoprotein titre (7 patients) or
high level of HCG (1 patient; HCG 23,000iuI`).
These were excluded. Patients who had had prior
chemotherapy were excluded. Patients with Stages
IIC, III and IV were included in the study. All but
4 Stage IIA and IIB patients were excluded since
these were treated with infradiaphragmatic
irradiation. Of the 4 IIA/IIB patients in the present
study 2 had had prior irradiation and 1 was not
irradiated because an accident in childhood has
resulted in extensive scarring to the abdominal wall
and groin. The fourth had a 5cm diameter mass
and received chemotherapy.
Treatment
Chemotherapy in the initial period of the study
consisted of cis-platinum, vinblastine and bleomycin
(PVB) (Einhorn & Donohue, 1977). Subsequently,
bleomycin, etoposide and cis-platinum (BEP)
(Peckham et al., 1983) were employed. Etoposide
and cis-platinum were employed in 1 patient. JM8
was employed in 5 patients as a single agent in a
dose of 400mgm-2 given as a 30min i.v. infusion
every 3-4 weeks (Calvert et al., 1982). Four patients
had 4 doses and one had 6. A sixth patient received
4 injections of JM8 for a mediastinal seminoma
with lung infiltration followed by 2 cycles of BEP,
since despite an excellent response, residual
thickening was present. Of the 44 patients, 31 (70%)
received 4 cycles of chemotherapy, two had 2 cycles,
three 5 cycles, seven 6 cycles and one 8 cycles. The
number of patients receiving each type of chemo-
therapy is shown in Table I.
Between 1978 and 1982 all but 7 patients had
involved site irradiation after chemotherapy. The 7
Table I Advanced seminoma: Outcome of treatment by
type of chemotherapy
(The Royal Marsden Hospital, 1978-1983)
No. of
Chemotherapy patients Relapses
Bleomycin, etoposide, cis-platinum 25 1
Etoposide, cis-platinum 1 0
Cis-platinum, vinblastine,
bleomycin 8 1
Carboplatin 5 1
Combination of above 5 2
Total 44 5
who did not, included one patient who had
undergone an extensive resection of an intra-
abdominal testis involving bladder and bowel, a
patient with Down's Syndrome treated with JM8, a
patient with lung infiltration and a primary
mediastinal seminoma, two patients with IIC
disease and one patient with IIIC disease.
Assessment ofresponse andfollow-up
One month after completion of chemotherapy
patients were reassessed with chest and abdominal
X-rays, CT scans of chest and abdomen, measure-
ment of serum AFP and HCG concentrations
and, where indicated, i.v. urography and repeat
Gallium 67 scans. A complete response was indicated
by the total absence of disease as judged clinically,
radiologically and biochemically. If residual masses
were identified these were monitored carefully at
subsequent follow-up visits. AFP and HCG serum
levels were measured at each visit in all patients.
Results
Of the 44 patients, 40 (90%) are alive and 4 have
died of germ-cell malignancy, 2 with non-
seminomatous metastases. Of those who are alive,
39 have remained continuously disease free for 12-
73 months (median 36 months) since treatment and
one is disease free 17 months after relapse following
initial chemotherapy.
Results by type ofchemotherapy
As shown in Table I the results obtained with the
different approaches used are comparable.
Influence ofprior radiotherapy
Of 13 patients who had been previously irradiated 3
(23%) have died compared with 1/31 (3%)
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Table II Advanced seminoma: Outcome of
chemotherapy in patients relapsing after
radiotherapy and previously untreated patients
(The Royal Marsden Hospital, 1978-1983)
Prior No. of No.
radiotherapy patients relapsing Dead
Yes 13 3 (23%) 3 (23%)'
No 31 2 (6%) 1 (3%)
Total 44 5 (11%) 4 (9%)
ap<0.03.
indicate a better survival for chemotherapy when
no prior radiotherapy was received by the patient
(log rank test X2=4.60, P=0.03).
Influence oftumour bulk
Table III shows the outcome of treatment in
relation to clinical stage in previously untreated
patients. Although 2 relapses occurred in patients
with bulky abdominal disease the overall results in
patients with extensive disease including bone and
liver were good, indicating that tumour volume
exerts less effect on treatment outcome with the
type of chemotherapy employed than is the case for
non-seminomatous tumours. Of the 5 patients
receiving JM8 as a single agent, 4 had bulky disease
(IIC or IIIC) of whom one failed and one had small
volume disease (IVOL1) and is in complete
remission.
Table III Advanced seminoma: Outcome of chemo-
therapy by stage in previously untreated patients
(The Royal Marsden Hospital, 1978-1983)
Stage/site No. of Continuously
presentation patients disease-Jfeea Deaths
Primary mediastinal 1 1
Primary mediastinal
+lung 2 2
IIA/IIB 4 4
IIC 17 15 1
IIIC 4 4
Iva 3 3
Total 31 29 (93%) 1 (3%)
aOne patient who relapsed and is disease-free after
salvage treatment is not included.
bPrimary mediastinal seminoma with bone and
extradural cord compression; disease-free 19 months.
Testicular primary with bone and liver involvement;
disease-free 65 months. Intra-abdominal testis with local
extension into bowel and bladder; disease-free 29 months.
Influence ofpost-chemotherapy radiotherapy
(Table IV)
Of 15 previously untreated patients receiving
involved site radiotherapy after chemotherapy, one
relapsed. Similarly there was only one relapse in 16
patients treated with chemotherapy alone. Although
follow-up times are shorter in the latter group
(median 19 months compared with 43 months), it is
unlikely that any significant differences will emerge
between these two approaches.
Table IV Advanced seminoma: Results of chemotherapy
±adjuvant radiotherapy
(The Royal Marsden Hospital, 1978-1983)
Observation
time
Elective involved (months)
site irradiation No. of No.
after chemotherapy patients relapsing Range Median
Yes 15 1 21-73 43
No 16 1 12-65 19
Assessment ofcomplete response
The results of reassessment one month following
completion of chemotherapy showed that only
14/44 (32%) had achieved complete clearance of
tumour. As shown in Table V when complete
response rates were related to bulk of disease most
complete responses were seen in patients with small
volume disease and the rate in bulky disease
patients was only 12%.
Surgery after chemotherapy
Four patients were explored after chemotherapy for
residual masses. All 4 had fibrotic masses with no
evidence of malignancy. One of the 4 patients
subsequently relapsed with an elevated serum AFP
level and at autopsy had undifferentiated malignant
teratoma metastases.
Patterns ofand time to relapse
Details on 5 relapsing patients are shown in Table
VI. In all cases relapse appeared in initially
involved sites and in one patient relapse occurred
after 2 years. In 2 patients relapse was associated
with raised serum AFP levels.
Pre-treatment serum HCG levels
As shown in Table VII, only 11% of patients had
completely normal serum HCG concentrations,
although in 52% of patients, the levels were low.
The highest level seen was 661 iu1-'. Pre-10 M.J. PECKHAM et al.
Table V Advanced seminoma: Disparity between conventional
response assessment and subsequent outcome
(The Royal Marsden Hospital, 1978-1983)
Complete disappearance
Volume oftumour No. of oftumour by one month Subsequent
at presentation patients post chemotherapy relapses
Non-bulkya 11 10 (91%) 1 (9%)
Bulky 33 4 (12%) 4 (12%)
Total 44 14 (32%) 5 (11%)
aBulky defined as abdominal status C, lung status L3 or
mediastinal mass>5 cm diameter.
Table VI Advanced seminoma: Details ofrelapse after chemotherapy
(The Royal Marsden Hospital, 1978-1983)
Markers at
Serum HCG relapse
level before
Prior chemo. Months to AFP HCG
Patient irradiation Stage (iu 1-) Chemotherapy relapse Site(s) (ngml-1) (iu1-1)
1 + IIC 8 PVB 15 ABDO 100 <1
2 + IIB 2 BEP 5 ABDO 63 <1
3 IIC 4 BEP 26 ABDO <5 3
4 IV bone/ 2 PVB/BEP 3 Bone <5 3
liver
5 IIC 9 JM8 1 ABDO <5 6
Table VII Advanced seminoma: Serum
HCG levels prior to chemotherapy
(The Royal Marsden Hospital,
1978-1983)
Serum HCG level No. of
(iu -1) patients %
<1 5 11
1-9 23 52
10-19 3a
20-49 6a
50-99 3a 37
100-199 2a
200-300 2a
aRelapsing patients.
chemotherapy HCG levels were low in all 5
relapsing patients (Table VI) suggesting that this is
not a significant prognostic factor at least when
combination chemotherapy is employed.
Toxicity
There were no deaths attributable to the effects of
chemotherapy. The toxicity of PVB, BEP and EP
has been described elsewhere (Einhorn and
Donohue, 1977; Peckham et al., 1983; Peckham &
Horwich, 1985). Of the 5 patients treated with JM8,
2 experienced nausea and vomiting with each
injection, 2 experienced some nausea but did not
vomit and one was asymptomatic for two injections
and experienced nausea and vomiting with two.
Hair loss did not occur and there was no
impairment of renal function or peripheral
neuropathy. Nadir blood counts were as follows:
White count, 2-3.9 x i0 ml-1; platelets, 37-
62 x 103ml-' and haemoglobin, 9.3-13.4GI l. The
gaps between injections of JM8 were as follows:
<21 days, 6 gaps; 22-28 days, 7 gaps; 29-35 days, 2
gaps with one interval of 36 days and one of 39
days.
Discussion
The present results together with those reported
from other centres show that seminoma is highly
sensitive to platinum-containing chemotherapy
(Table VIII). More limited data indicate that
platinum analogues are active as single-agents. As
shown in Table IX Samuels et al. (1983) haveTREATMENT OF ADVANCED SEMINOMA 11
Table VIII Advanced seminoma: Results of treatment with cis-platinum containing combination
chemotherapy
No. of
No. achieving Currently relapses
complete disease in CR lime to
No. of remission free patients relapse
Authors Drugs patients (CR) (%) (%) (%) (months)
Van Oosterom et al. Cis-platinum
(1984)' +vinblastine
bleomycin
+adriamycin 73 51 (70) NS NS NS
Oliver (1984) Cis-platinum
+vinblastine
bleomycin 12 NS 10 (83) NS NS
Morse et al. Cis-platinum
(1983) +vinblastine
actinomycin-D
cyclophosphamide
bleomycin 22 19 (86)b 18 (82) 1/19 (5) NS
Simon et al. Cis-platinum
(1983) +vinblastine
antinomycin-D,
cyclophosphamide
bleomycin 10 10 (100) 10 (100) 3/10 (30) 6, 7, 8
Peckham et al. Cis-platinum
(present series) +bleomycin
etoposide and/or
vinblastine 39 13 (33) 36 (92) 0/13
(see text)
aCollected data from Indiana, Netherlands and Madrid.
bIncludes surgical and clinical assessment, using clinical criteria only 9/22 (40%) achieved CR.
Table IX Advanced seminoma: Outcome of treatment with platinum
analogues as single agents
No. of
Authors Chemotherapy patients No. disease-free
Samuels et al. (1983) Cis-platinum 32 30 (22>2 years)
Oliver (1984) Cis-platinum 14 10 (median follow-up
14 months)
Peckham et al.a JM8b 7 6 (6-32 months)
(present series) (median 15 months)
aIncludes two further patients observed for <1 year.
bOne patient received radiotherapy after JM8.
reported 32 patients treated with cis-platinum
±cyclophosphamide of whom 30 are in continuing
complete remission, 27 for more than 18 months. In
their study cis-platinum was given weekly but it is
not clear how many patients also had cyclo-
phosphamide. Oliver (1984) has reported on 14
patients treated with cis-platinum alone of whom 10
are disease free. Of 10 untreated patients 9 are
disease free. Preliminary data from the present
study employing JM8 as a single agent is
encouraging with 4/5 patients disease free at 12, 16,
28 and 32 months. A further patient disease free at
14 months achieved an excellent response with 4
doses of JM8 and then received 2 cycles of BEP as
consolidation because of residual mediastinal
widening. Obviously further information is required12 M.J. PECKHAM et al.
before the role of carboplatin in the management of
seminoma can be assessed.
A potential disadvantage of employing single
agent chemotherapy in seminoma is the possibility
that unrecognized non-seminomatous tumour com-
ponents may be present but are not subject to
control resulting in drug resistant tumour at
relapse. In the present series 2/39 patients treated
with combination chemotherapy had raised serum
AFP levels at relapse. None of the patients treated
with JM8 as a single agent have relapsed as a non-
seminoma. It is not stated whether the two deaths
in the series reported by Samuels and his colleagues
were treatment-related or due to seminoma or non-
seminoma, however, 30/32 are disease free which
suggests that the risk of unrecognized and un-
controlled non-seminomatous components is unlikely
to pose a major problem. The present data show
that moderate elevation of serum HCG levels is
common in metastatic seminoma and appears not to
influence the results of combination chemotherapy.
Whether this will remain true for single agent
platinum chemotherapy remains to be demonstrated.
So far as the use of combination chemotherapy is
concerned, the apparent effectiveness of platinum
analogues as single agents raises doubts about the
contribution of other drugs included in the
regimens summarized in Table VIII. Samuels et al.
(1983) have reported on 18 patients treated with
bleomycin, cyclophosphamide, vincristine, metho-
trexate and 5 fluorouracil of whom 10 achieved CR
but five subsequently failed. All 7 patients treated
with vinblastine and bleomycin failed to achieve CR
and died. Since the latter combination resulted in
CR rates of - 50% in patients with non-
seminomatous germ-cell tumours, it appears that
the spectrum of drugs active in seminoma and non-
seminoma may differ substantially. A major
difference between the present series and those
previously reported is the complete response (CR)
rate of 32% which is considerably lower than the
figure obtained at other centres. This difference is
likely to reflect differences in the time at which
response was assessed as well as the methods of
assessment. It is clear that other centres have also
observed residual masses after chemotherapy. Thus
in the memorial series of 22 patients, only 9 (40%)
achieved complete disappearance of masses and 10
were submitted to surgery for residual abnormalities
(Morse et al., 1983). All 10 patients were histo-
logically negative. Of the 10 patients reported by
Simon et al. (1983) seven were explored after
chemotherapy and all were histologically negative.
It is clear that residual masses are common after
completion of chemotherapy for advanced
seminoma, particularly if disease is bulky initially.
These masses resolve slowly over months, and in
some instances, years. Surgical exploration is
complicated by the densely adherent fibrotic nature
of the residuum and generally proves negative. In
addition to the 17 patients undergoing laparotomy
as described above four patients in the present
series were explored and all were negative. Surgery
is therefore not advocated, although careful
monitoring of residual masses is essential. In this
context preliminary data indicate that placental
alkaline phosphatase is likely to prove a useful
marker in seminoma (Lange et al., 1982).
Recurrences can occur in patients achieving
complete remission and those who are histologically
negative at surgery. As shown in Table VIII 1/19
CR patients in the series of Morse et al. (1983)
relapsed as did 3/10 patients reported by Simon et
al. (1983). In the latter group 3/7 patients, who were
histologically negative at surgery relapsed as did 1/4
in the present series. None of 10 surgically negative
patients reported by Morse relapsed.
Although the role of adjuvant radiotherapy after
chemotherapy has not been formally investigated in
a randomized trial, limited data summarized in
Table IV suggest that it is unnecessary. Gradual
resolution of residual masses occurs and as noted
above the histology of resected tissue has generally
proved negative.
To date there is scanty information on time to
relapse after combination chemotherapy for
advanced seminoma. Relapses in the present series
occurred at 1, 3, 5, 15 and 26 months after
chemotherapy and in the series of Simon et al.
(1983) at 6, 7 and 8 months. Hence 6/8 relapses
have been within the first year of chemotherapy.
In conclusion, seminoma is a highly chemo-
responsive tumour in which the influence of tumour
volume on the outcome of chemotherapy appears to
be less obvious than is the case for non-seminomas
although residual masses are commonly present one
month after completion of chemotherapy. The
results of surgery show that such masses are almost
invariably negative histologically and often densely
fibrotic. Spontaneous resolution of residual masses
occurs, often over a period of months or years.
There is no evidence that post-chemotherapy radio-
therapy is contributory.
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